Search

26 Jul 2024: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Cancer is a disease of mutation, and the most commonly mutated

21 Jul 2023: Alan Fersht. Tumour suppressor p53 structure and drug discovery. Alan Fersht was a Natural Sciences undergraduate and Chemistry postgraduate at Gonville and Caius from 1962-68. ... Cancer is a disease of mutation, and the most commonly mutated protein by

26 Jan 2021: Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... Tumour Suppressor p53. Structural Biology and Drug Discovery. Alan Fersht. MRC Laboratory of Molecular Biology.

27 Jul 2024: a downstream conduit for many (perhaps all) oncogenic growth signals, and a second mouse that models pharmacological restoration of the p53 tumour suppressor, which is functionally inactivated in most human cancers. ... Since it is the endogenous

Alan rejoined the LMB in 2010, where he continued his work on protein folding, misfolding and disease, concentrating on the tumour suppressor p53 until the end of 2017. ... n. Cancer is a disease of mutation, and the most commonly mutated protein by far

27 Jul 2024: The net result is hyperplasia in several tissues, which is exacerbated by the additional loss of the tumour suppressor protein p53. ... p53 is non-functional in the majority of human tumours and mice lacking p53 are prone to tumour development.

26 Jul 2024: His work is now focussed on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53 – the so-called “Guardian of the Genome” – in order to design novel

27 Jul 2024: During the conference the Prof. Karen Vousden from The Crick Institute, London, was awarded of the CDD Award 2018 for her pioneering studies on the function of the tumour suppressor protein ... p53 in the response to environmental stressors.

23 Feb 2024: For example, we recently showed that hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation

20 May 2024: Alan Fersht - Tumour suppressor p53 structure and drug discovery.

23 Feb 2024: For example, hPSCs recurrently acquire cancer-associated mutations in the tumour suppressor TP53 (p53) that promote growth in culture and would increase the risk of cancer formation from transplanted cells (Merkle ... Human pluripotent stem cells

21 Jul 2023: Tumour suppressor p53 structure and drug discovery. LMB Division - Protein and Nucleic Acid Chemistry.

can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

{"id":61,"date":"2012-06-25T10:03:42","date_gmt":"2012-06-25T10:03:42","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/?page_id=61"},"modified":"2024-05-20T14:39:16","modified_gmt":"2024-05-20T13:39:16","slug":"protein-and-nucleic-acid-ch

20 Oct 2017: can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

nAlan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

{"id":18741,"date":"2020-08-04T17:10:07","date_gmt":"2020-08-04T16:10:07","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=18741"},"modified":"2020-08-04T17:10:09","modified_gmt":"2020-08-04T16:10:09","slug":"alan-fersht-and-marta-zlatic-win-roy

29 Nov 2011: T. M. Rippin, TH. Mechanistic studies of the tumour suppressor p53: a basis for rational anti-cancer drug design. ... Stability, folding and evolution of the tumour suppressor protein p16. L.

23 Feb 2024: 2009) NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing ... and Colombo, E.(2011) The lymphoma-associated NPM-ALK oncogene elicits a

24 Sep 2010: Alan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.